Reply to: Utility of Serum S100B as a Marker in SLE Patients During and After the SARS-Cov-2 Pandemic
- PMID: 35649743
- PMCID: PMC9130680
- DOI: 10.1016/j.arcmed.2022.05.005
Reply to: Utility of Serum S100B as a Marker in SLE Patients During and After the SARS-Cov-2 Pandemic
Conflict of interest statement
Conflict of Interest None.
Comment on
-
Emerging Roles of Coronavirus in Autoimmune Diseases.Arch Med Res. 2021 Oct;52(7):665-672. doi: 10.1016/j.arcmed.2021.03.012. Epub 2021 Apr 8. Arch Med Res. 2021. PMID: 33875273 Free PMC article. Review.
-
Utility of Serum S100B as A Marker in Systemic Lupus Erythematosus Patients During and After the SARS-CoV-2 Pandemic.Arch Med Res. 2022 Jul;53(5):543-544. doi: 10.1016/j.arcmed.2022.05.004. Epub 2022 May 25. Arch Med Res. 2022. PMID: 35637047 Free PMC article. No abstract available.
References
-
- Bonometti R., Sacchi M.C., Stobbione P., et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24:9695–9697. - PubMed
-
- Shayestehpour M., Zamani B. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24:11474. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous